STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity

Ionis Pharmaceuticals (IONS) EVP Baroldi reports option exercises and stock sales

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Ionis Pharmaceuticals EVP and Chief Business Officer Joseph Baroldi reported a mix of option exercises and share sales in Ionis stock. In early March 2026, he and his spouse exercised non-qualified stock options into common stock and then sold a net 6,659 shares, including 4,096 directly owned shares at $79.36 per share.

Additional indirect sales by his spouse involved smaller blocks such as 2,088 shares at $80.4079 and 36 shares at $81.01, alongside option-related acquisitions at exercise prices of $32.60 and $56.78. Footnotes state that these sales were made under Rule 10b5-1 trading plans adopted by Baroldi and his spouse.

Positive

  • None.

Negative

  • None.
Insider Baroldi Joseph
Role EVP, Chief Business Officer
Sold 6,659 shs ($531K)
Type Security Shares Price Value
Exercise Non-Qualified Stock Option (right to buy) 201 $0.00 --
Exercise Non-Qualified Stock Option (right to buy) 238 $0.00 --
Exercise Common Stock 238 $56.78 $14K
Sale Common Stock 238 $80.00 $19K
Exercise Common Stock 201 $32.60 $7K
Sale Common Stock 201 $80.00 $16K
Exercise Non-Qualified Stock Option (right to buy) 879 $0.00 --
Exercise Non-Qualified Stock Option (right to buy) 820 $0.00 --
Sale Common Stock 4,096 $79.36 $325K
Exercise Common Stock 820 $56.78 $47K
Exercise Common Stock 879 $32.60 $29K
Sale Common Stock 2,088 $80.4079 $168K
Sale Common Stock 36 $81.01 $3K
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 1,769 shares (Indirect, by Spouse); Common Stock — 4,585 shares (Indirect, by Spouse); Common Stock — 41,317 shares (Direct)
Footnotes (1)
  1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.94 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Baroldi Joseph
(Last) (First) (Middle)
2855 GAZELLE COURT
(Street)
CARLSBAD CA 92010
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Business Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/03/2026 S 4,096(1) D $79.36 41,317 D
Common Stock 03/03/2026 M 820 A $56.78 5,592 I by Spouse
Common Stock 03/03/2026 M 879 A $32.6 6,471 I by Spouse
Common Stock 03/03/2026 S 2,088(2) D $80.4079(3) 4,383 I by Spouse
Common Stock 03/03/2026 S 36(2) D $81.01 4,347 I by Spouse
Common Stock 03/04/2026 M 238 A $56.78 4,585 I by Spouse
Common Stock 03/04/2026 S 238(2) D $80 4,347 I by Spouse
Common Stock 03/04/2026 M 201 A $32.6 4,548 I by Spouse
Common Stock 03/04/2026 S 201(2) D $80 4,347 I by Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $32.6 03/03/2026 M 879 01/03/2023 01/02/2032 Common Stock 879 $0.0 1,970 I by Spouse
Non-Qualified Stock Option (right to buy) $32.6 03/04/2026 M 201 01/03/2023 01/02/2032 Common Stock 201 $0.0 1,769 I by Spouse
Non-Qualified Stock Option (right to buy) $56.78 03/03/2026 M 820 01/04/2022 01/03/2028 Common Stock 820 $0.0 4,104 I by Spouse
Non-Qualified Stock Option (right to buy) $56.78 03/04/2026 M 238 01/04/2022 01/03/2028 Common Stock 238 $0.0 3,866 I by Spouse
Explanation of Responses:
1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
2. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.94 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
By: Patrick R. O'Neil, attorney-in-fact For: Joseph T. Baroldi 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR